A Phase 1 interventional study of LY3502970 in Healthy and Obese, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one is the 20th largest by enrollment, is one of 6 that started in 2023, is one of 6 in phase 1, and was the 4th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 102nd largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 40 in phase 1, and was the 28th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a once daily (QD) oral dose of LY3502970 in the tablet or capsule formulation, depending on the period of the study, throughout Periods 1 to 11 as follows: * Period 1 (Day 1-7): 0.8 milligram (mg) LY3502970 tablet (fasted state) * Period 2 (Day 8-14): 2 mg LY3502970 capsule (fasted state) * Period 3 (Day 15-21): 2.5 mg LY3502970 tablet (fasted state) * Period 4 (Day 22-28): 5 mg LY3502970 tablet (fasted state) * Period 5 (Day 29-35): 8 mg LY3502970 capsule (fasted state) * Period 6 (Day 36-42): 10 mg LY3502970 tablet (fasted state) * Period 7 (Day 43-49): 16 mg LY3502970 capsule (fasted state) * Period 8 (Day 50-56): 20 mg LY3502970 tablet (fasted state) * Period 9 (Day 57-63): 36 mg LY3502970 capsule (fasted state) * Period 10 (Day 64-70): 36 mg LY3502970 capsule or 37.5 mg LY3502970 tablet (fed state) * Period 11 (Day 71-77): 37.5 mg LY3502970 tablet (fasted state)
Drug: LY3502970
Participants after completion of Part A (Periods 1-11), in Part B received a QD oral dose of LY3502970 as follows: * Period 12 (Day 78-84): 45 mg LY3502970 tablet (fasted state) * Period 13 (Day 85-91): 60 mg LY3502970 tablet (fasted state)
Drug: LY3502970
Participants after completion of Part A (Periods 1-11), in Part B received a QD oral dose of LY3502970 as follows: * Period 12 (Day 78-84): 35 mg LY3502970 tablet (fasted state) * Period 13 (Day 85-91): 35 mg LY3502970 tablet (fasted state)
Drug: LY3502970
Participants after completion of Part A (Periods 1-11), in Part B received a QD oral dose of LY3502970 as follows: * Period 12 (Day 78-84): 36 mg LY3502970 dual-fill (DF) capsule (fasted state) * Period 13 (Day 85-91): 36 mg LY3502970 extemporaneously prepared blended (EPB) capsule (fasted state)
Drug: LY3502970
Administered orally.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13
PK: AUC\[0-24\] of LY3502970 in fasted state
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13
PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13
PK: Cmax of LY3502970 in fasted state
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13
PK: Tmax of LY3502970 in fasted state
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of each treatment period in Part A: Periods 1-9, 11 and Part B: Periods 12-13
PK: Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fed State - Part A: Period 10
PK: AUC\[0-24\] of LY3502970 in fed state
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of Part A: Period 10 (Day 70)
PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fed State - Part A: Period 10
PK: Cmax of LY3502970 in fed state
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of Part A: Period 10 (Day 70)
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fed State - Part A: Period 10
PK: Tmax of LY3502970 in fed state
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours post-dose on Day 7 of Part A: Period 10 (Day 70)
The study had two sequential parts ; Part A and Part B. Part A consisted of dosing periods 1 to 11 and Part B consisted of dosing periods 12 and 13. Participants enrolled in the study, began in Part A, and continued into Part B.
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 52 | 0 | 0 | 0 |
| Completed | 50 | 0 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 50 | 0 | 0 | 0 |
| Completed | 50 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 50 | 0 | 0 | 0 |
| Completed | 49 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 49 | 0 | 0 | 0 |
| Completed | 49 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 49 | 0 | 0 | 0 |
| Completed | 46 | 0 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Use of prohibited concomitant medication | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study requirements | 1 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 46 | 0 | 0 | 0 |
| Completed | 46 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 46 | 0 | 0 | 0 |
| Completed | 45 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 45 | 0 | 0 | 0 |
| Completed | 42 | 0 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 21 | 0 | 0 | 0 |
| Completed | 20 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 21 | 0 | 0 | 0 |
| Completed | 21 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 41 | 0 | 0 | 0 |
| Completed | 40 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 (Periods 1 to 11) | Part B: 35 mg LY3502970 / 35 mg LY3502970 (Periods 12 to 13) | Part B: 45 mg LY3502970 / 60 mg LY3502970 (Periods 12 to 13) | Part B: 36 mg LY3502970 DF / 36 mg LY3502970 EPB (Periods 12 to 13) |
|---|---|---|---|---|
| Started | 0 | 7 | 21 | 12 |
| Completed | 0 | 7 | 21 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
PK: AUC\[0-24\] of LY3502970 in fasted state
| nanogram*hour per milliliter (ng*h/mL) | Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State) | Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State) | Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State) | Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State) | Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State) | Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State) | Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State) | Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State) | Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State) | Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State) | Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13 | 90.8 ± 27 | 199 ± 34 | 294 ± 31 | 548 ± 29 | 700 ± 42 | 1080 ± 32 | 1250 ± 40 | 1970 ± 48 | 1580 ± 72 | 3680 ± 47 | 3730 ± 37 | 4080 ± 40 | 4100 ± 51 | 6410 ± 49 | 1950 ± 59 | 3030 ± 45 |
PK: Cmax of LY3502970 in fasted state
| nanograms per milliliter (ng/mL) | Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State) | Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State) | Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State) | Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State) | Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State) | Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State) | Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State) | Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State) | Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State) | Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State) | Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13 | 6.08 ± 26 | 13.5 ± 39 | 19.9 ± 34 | 36.6 ± 35 | 45.1 ± 49 | 69.8 ± 34 | 73.5 ± 58 | 126 ± 57 | 100 ± 89 | 257 ± 54 | 234 ± 39 | 295 ± 39 | 275 ± 49 | 460 ± 55 | 109 ± 58 | 203 ± 48 |
PK: Tmax of LY3502970 in fasted state
| hours | Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State) | Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State) | Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State) | Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State) | Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State) | Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State) | Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State) | Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State) | Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State) | Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State) | Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13 | 6.00 (3.98 to 8.00) | 6.00 (0.00 to 12.00) | 6.00 (2.00 to 8.02) | 6.00 (2.00 to 23.83) | 8.00 (1.00 to 12.00) | 6.00 (0.00 to 12.00) | 6.00 (0.00 to 23.83) | 8.00 (0.00 to 23.83) | 8.00 (2.00 to 23.87) | 6.03 (1.00 to 12.00) | 8.00 (4.00 to 12.00) | 4.03 (4.00 to 8.00) | 4.07 (2.07 to 8.00) | 8.00 (2.00 to 12.00) | 5.92 (1.92 to 7.92) | 6.88 (1.92 to 7.93) |
PK: AUC\[0-24\] of LY3502970 in fed state
| nanogram*hour per milliliter (ng*h/mL) | Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State) | Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State) |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fed State - Part A: Period 10 | 1230 ± 139 | 3170 ± 36 |
PK: Cmax of LY3502970 in fed state
| nanograms per milliliter (ng/mL) | Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State) | Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State) |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of LY3502970 in Fed State - Part A: Period 10 | 81.0 ± 104 | 203 ± 51 |
PK: Tmax of LY3502970 in fed state
| hours | Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State) | Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State) |
|---|---|---|
| PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Fed State - Part A: Period 10 | 12.00 (0.00 to 23.83) | 6.00 (0.00 to 23.83) |
Collected over Baseline to end of follow-up (up to 15 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State) | 0/52 (0%) | 0/52 (0%) | 7/52 (13.5%) |
| Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State) | 0/50 (0%) | 0/50 (0%) | 6/50 (12%) |
| Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State) | 0/50 (0%) | 0/50 (0%) | 3/50 (6%) |
| Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State) | 0/50 (0%) | 0/50 (0%) | 8/50 (16%) |
| Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State) | 0/49 (0%) | 0/49 (0%) | 13/49 (26.5%) |
| Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State) | 0/49 (0%) | 0/49 (0%) | 9/49 (18.4%) |
| Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State) | 0/46 (0%) | 0/46 (0%) | 4/46 (8.7%) |
| Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State) | 0/46 (0%) | 1/46 (2.2%) | 4/46 (8.7%) |
| Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State) | 0/45 (0%) | 1/45 (2.2%) | 2/45 (4.4%) |
| Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State) | 0/21 (0%) | 0/21 (0%) | 3/21 (14.3%) |
| Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State) | 0/21 (0%) | 0/21 (0%) | 12/21 (57.1%) |
| Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State) | 0/41 (0%) | 0/41 (0%) | 12/41 (29.3%) |
| Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State) | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State) | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State) | 0/21 (0%) | 0/21 (0%) | 4/21 (19%) |
| Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State) | 0/21 (0%) | 0/21 (0%) | 5/21 (23.8%) |
| Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State) | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State) | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Event | Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State) | Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State) | Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State) | Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State) | Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State) | Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State) | Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State) | Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State) | Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State) | Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State) | Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State) | Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State) | Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chest painGeneral disorders | 0/52 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/46 | 0/46 | 1/45 | 0/21 | 0/21 | 0/41 | 0/7 | 0/7 | 0/21 | 0/21 | 0/12 | 0/12 |
| AppendicitisInfections and infestations | 0/52 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/46 | 1/46 | 0/45 | 0/21 | 0/21 | 0/41 | 0/7 | 0/7 | 0/21 | 0/21 | 0/12 | 0/12 |
| Event | Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State) | Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State) | Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State) | Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State) | Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State) | Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State) | Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State) | Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State) | Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State) | Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State) | Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State) | Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State) | Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State) | Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State) | Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/52 | 0/50 | 0/50 | 0/50 | 1/49 | 2/49 | 0/46 | 1/46 | 0/45 | 2/21 | 4/21 | 6/41 | 1/7 | 0/7 | 2/21 | 1/21 | 1/12 | 5/12 |
| HeadacheNervous system disorders | 2/52 | 0/50 | 2/50 | 6/50 | 1/49 | 0/49 | 0/46 | 0/46 | 0/45 | 0/21 | 4/21 | 5/41 | 0/7 | 0/7 | 0/21 | 1/21 | 0/12 | 2/12 |
| DyspepsiaGastrointestinal disorders | 1/52 | 0/50 | 0/50 | 2/50 | 5/49 | 1/49 | 0/46 | 2/46 | 0/45 | 0/21 | 2/21 | 3/41 | 1/7 | 0/7 | 0/21 | 1/21 | 0/12 | 0/12 |
| FlatulenceGastrointestinal disorders | 0/52 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/46 | 0/46 | 0/45 | 0/21 | 0/21 | 0/41 | 1/7 | 0/7 | 0/21 | 0/21 | 0/12 | 0/12 |
| VomitingGastrointestinal disorders | 2/52 | 0/50 | 0/50 | 1/50 | 2/49 | 0/49 | 1/46 | 1/46 | 0/45 | 0/21 | 1/21 | 5/41 | 1/7 | 0/7 | 1/21 | 3/21 | 0/12 | 1/12 |
| IntertrigoSkin and subcutaneous tissue disorders | 0/52 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/46 | 0/46 | 0/45 | 0/21 | 1/21 | 0/41 | 0/7 | 1/7 | 0/21 | 0/21 | 0/12 | 0/12 |
| ConstipationGastrointestinal disorders | 2/52 | 5/50 | 0/50 | 1/50 | 2/49 | 6/49 | 0/46 | 0/46 | 0/45 | 1/21 | 2/21 | 0/41 | 0/7 | 0/7 | 0/21 | 1/21 | 1/12 | 0/12 |
| Abdominal distensionGastrointestinal disorders | 0/52 | 0/50 | 0/50 | 0/50 | 2/49 | 0/49 | 0/46 | 0/46 | 0/45 | 0/21 | 1/21 | 1/41 | 0/7 | 0/7 | 2/21 | 0/21 | 0/12 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 0/52 | 1/50 | 0/50 | 0/50 | 3/49 | 0/49 | 3/46 | 1/46 | 2/45 | 0/21 | 1/21 | 1/41 | 0/7 | 0/7 | 0/21 | 0/21 | 1/12 | 1/12 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/52 | 0/50 | 1/50 | 0/50 | 1/49 | 1/49 | 0/46 | 0/46 | 0/45 | 0/21 | 1/21 | 0/41 | 0/7 | 0/7 | 0/21 | 0/21 | 0/12 | 1/12 |
All enrolled participants (period 1).
| Age, Continuous(years) | Part A: LY3502970 (Periods 1 to 11) |
|---|---|
| Mean | 42.3 ± 11.9 |
| Sex: Female, Male(Participants) | Part A: LY3502970 (Periods 1 to 11) |
|---|---|
| Female | 23 |
| Male | 29 |
| Ethnicity (NIH/OMB)(Participants) | Part A: LY3502970 (Periods 1 to 11) |
|---|---|
| Hispanic or Latino | 20 |
| Not Hispanic or Latino | 32 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Part A: LY3502970 (Periods 1 to 11) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 25 |
| White | 27 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Part A: LY3502970 (Periods 1 to 11) |
|---|---|
| United States | 52 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2023 to primary completion in Sep 2023, 4 months.
Results were first posted in Jul 2026, 2 years 9 months after primary completion.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron